NewslettersMammary Cell News Anti-Tumor Activity and Biomarker Analysis for TROP2-Antibody Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models By Jamie Kang - November 27, 2024 0 81 Scientists tested the activity of datopotamab deruxtecan in a panel of breast cancer patient-derived xenografts varying in TROP2 expression. [Clinical Cancer Research] Abstract